The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bortezomib in combination with gemcitabine (GEM) and cisplatin (CDDP) in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC): A Hellenic Oncology Research Group multicenter phase II study.
Sofia Agelaki
No relevant relationships to disclose
Athanasios Kotsakis
No relevant relationships to disclose
Emmanouil Kontopodis
No relevant relationships to disclose
Nikolaos K. Kentepozidis
No relevant relationships to disclose
Konstantinos N. Syrigos
No relevant relationships to disclose
Nikolaos Ziras
No relevant relationships to disclose
Georgia Filippa
No relevant relationships to disclose
Lampros Vamvakas
No relevant relationships to disclose
Dimitrios Mavroudis
No relevant relationships to disclose
Vassilis Georgoulias
Consultant or Advisory Role - Amgen; Novartis; Pfizer
Research Funding - GlaxoSmithKline; Sanofi